Reduced Hemodynamic Response to Vasopressin in Obese Septic Shock Patients
Overview
In septic shock patients receiving adjunct arginine vasopressin (AVP), those with obesity exhibited an attenuated hemodynamic response characterized by a lack of reduction or even increase in norepinephrine (NE) requirements. This diminished response was not improved by BMI-adjusted AVP dosing, suggesting that fixed-dose AVP may lead to underexposure or altered pharmacodynamics in obese patients.
Background
Obesity is common in intensive care settings and can alter drug pharmacokinetics and pharmacodynamics, necessitating individualized dosing strategies. Arginine vasopressin is used adjunctively with norepinephrine in catecholamine-resistant septic shock, but responsiveness varies widely. Prior studies indicated obesity is linked to reduced hemodynamic response and prolonged vasopressor dependency with AVP, but the underlying mechanisms—whether physiological or dosage-related—remain unclear. This study analyzed BMI-stratified responses to AVP and evaluated the impact of BMI-adjusted dosing on NE requirements.
Data Highlights
BMI Group
Number of Patients
Baseline NE Dose (mcg/kg/min, median [IQR])
NE Dose Change (% per hour)
NE Dose Change (mcg/kg/min per hour)
Normal Weight (BMI < 25)
66
0.49 [0.35–0.74]
−6.1% (95% CI 1.7–10.6)
−0.04 (95% CI 0.02–0.06)
Overweight (BMI 25–29.9)
69
0.40 [0.33–0.53]
−2.0% (95% CI −6.3–2.4)
−0.01 (95% CI −0.03–0.01)
Obesity (BMI ≥ 30)
65
0.37 [0.28–0.47]
+5.5% (95% CI 1.0–10.0)
+0.02 (95% CI 0.00–0.04)
Key Findings
Normal weight patients showed a significant hourly reduction in NE dose after AVP initiation, whereas obese patients exhibited an increase in NE dose requirements.
Each 5 kg/m2 increase in BMI was associated with a 2.7% per hour less reduction in NE dose, indicating a dose-response relationship between BMI and AVP effectiveness.
Higher AVP doses correlated with decreased NE requirements in normal weight patients but were associated with increased NE requirements in overweight patients and showed no significant effect in obese patients.
BMI-adjusted AVP dosing did not significantly improve NE dose reduction compared to fixed-dose AVP across any BMI category.
Baseline characteristics such as lactate, pH, MAP, and SOFA scores were similar across BMI groups, but obese patients had lower baseline NE doses and higher prevalence of abdominal sepsis and gram-negative infections.
Extended observation up to 5 hours post-AVP initiation confirmed the persistence of BMI-dependent differences in NE dose trajectories.
Clinical Implications
Clinicians should be aware that obese septic shock patients may have a reduced hemodynamic response to fixed-dose adjunctive AVP, potentially necessitating alternative vasopressor strategies or dosing considerations. BMI-adjusted AVP dosing alone may not overcome this attenuated response, highlighting the need for further research into pharmacodynamic mechanisms and individualized treatment approaches in this population.
Conclusion
Obesity is independently associated with an attenuated hemodynamic response to adjunctive vasopressin in septic shock, reflected by increased norepinephrine requirements despite AVP therapy. This phenomenon appears not to be corrected by BMI-adjusted AVP dosing, suggesting intrinsic physiological or pharmacodynamic factors contribute to this reduced responsiveness.
References
1 -- Obesity and altered drug pharmacokinetics in ICU patients
2 -- Variability in vasopressin responsiveness in septic shock
3 -- Multicenter registry study on obesity and vasopressin response
